Deep inside the cells of the human brain, a war of waste is quietly escalating in people with Parkinson's disease — and Jialiu Zeng may have found a way to tip the battle in favor of health. Lysosomes, the cell's recycling centers, are losing their acidic punch, allowing toxic proteins to pile up like uncollected garbage. Now, research from Zeng, an assistant professor of biomedical and chemical engineering, shows that impossibly small nanoparticles could restore these cellular cleanup crews and slow disease progression at its source.
This matters because Parkinson's is a relentless thief of movement and dignity. When lysosomes fail to maintain their acidic environment — something like the stomach acid that breaks down food — they can no longer clear damaged proteins and cellular waste. That buildup triggers a domino effect: neurons die, movement deteriorates, and the disease advances. Most current treatments address symptoms after damage has already occurred. Zeng's approach is fundamentally different. Rather than mopping up after the spill, her acidic nanoparticles restore the cell's own ability to clean house.
The strategy sounds deceptively simple but represents a genuine breakthrough in how scientists think about neurodegenerative disease. The nanoparticles are spherical structures no larger than 10 to the minus ninth power — tinier than a cell itself, formed from long, flexible polymer chains that tangle together like yarn. Because of their size, cells absorb them readily. Once inside, the nanoparticles break apart and release acid, re-establishing the acidic environment lysosomes need to function. In both cell and animal models of Parkinson's disease, this approach reduced toxic protein aggregation, the hallmark of the condition, and protected the brain cells responsible for movement that are progressively lost during the disease.
The research, published in April in Advanced Healthcare Materials, emerged from collaboration between Zeng's lab in the College of Engineering and Computer Science and assistant professor Chih Hung Lo's lab in the Department of Biology. Both labs are part of the university's interdisciplinary neuroscience program and share a focus on understanding diseases including Alzheimer's, Parkinson's, and multiple sclerosis. Zeng describes the work with characteristic precision: "Rather than simply trying to block damage after it occurs, this approach aims to restore the cell's own ability to clear toxic material and maintain homeostasis."
What makes this research particularly promising is its potential reach beyond Parkinson's. Zeng is already testing the nanoparticle strategy across multiple disease areas, including metabolic disorders. Her work suggests that lysosomal dysfunction may serve as an early warning sign of disease, a pattern that appears across Parkinson's, obesity, and diabetes. This insight has launched a parallel effort: Zeng and Lo are now developing biomarkers to detect changes in lysosomal pH at early stages, potentially allowing doctors to intervene before irreversible damage accumulates.
The challenge ahead is formidable but navigable. The blood-brain barrier, the brain's protective security system, makes it difficult for nanoparticles to reach their target. Zeng's next steps focus on engineering better delivery mechanisms to cross this barrier. If successful, the implications are profound — a treatment that addresses disease at its cellular root, that could be adapted to multiple conditions, and that restores the body's own healing systems rather than simply masking symptoms. For people living with Parkinson's and the neurodegenerative diseases that follow similar pathways, that distinction could mean everything.